Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term postmenopausal women. Found 25 abstracts

no pagination
Eliassen AH, Hendrickson SJ, Brinton LA, Buring JE, Campos H, Dai Q, Dorgan JF, Franke AA, Gao YT, Goodman MT, Hallmans G, Helzlsouer KJ, Hoffman-Bolton J, Hulteen K, Sesso HD, Sowell AL, Tamimi RM, Toniolo P, Wilkens LR, Winkvist A, Zeleniuch-Jacquotte A, Zheng W, Hankinson SE. Circulating Carotenoids and Risk of Breast Cancer: Pooled Analysis of Eight Prospective Studies. Journal of the National Cancer Institute. 2012 Dec;104(24):1905-16.   PMCID: PMC3525817
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network. Cancer. 2012 Nov;118(22):5463-72.   PMCID: PMC 36116559
Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, Hainsworth E, Montor WR, Wong J, Park JG, Lokko N, Logvinenko T, Ramachandran N, Godwin AK, Marks J, Engstrom P, LaBaer J. Protein Microarray Signature of Autoantibody Biomarkers for the Early Detection of Breast Cancer. Journal of Proteome Research. 2011 Jan;10(1):85-96.   PMCID: PMC3158028
Dorgan JF, Liu L, Klifa C, Hylton N, Shepherd JA, Stanczyk FZ, Snetselaar LG, Van Horn L, Stevens VJ, Robson A, Kwiterovich PO, Lasser NL, Himes JH, Gabriel KP, Kriska A, Ruder EH, Fang CY, Barton BA. Adolescent Diet and Subsequent Serum Hormones, Breast Density, and Bone Mineral Density in Young Women: Results of the Dietary Intervention Study in Children Follow-up Study. Cancer Epidemiology Biomarkers & Prevention. 2010 Jun;19(6):1545-56.   PMCID: PMCID: PMC2883023 [Available on 2010/12/1]
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, Natl Surgical Adjuvant Breast B. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research. 2010 Jun;3(6):696-706.   PMCID: PMC2935331
Brauch H, Jordan VC. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach?. European Journal of Cancer. 2009 Sep;45(13):2274-83.   PMCID: not NIH funded
Svahn TH, Niland JC, Carlson RW, Hughes ME, Ottesen RA, Theriault RL, Edge SB, Schott AF, Bookman MA, Weeks JC. Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer. Journal of the National Comprehensive Cancer Network. 2009 Feb;7(2):115-21.   PMCID: No NIH
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Apr;295(14):1658-67.
Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: Implications for biomarkers of susceptibility and cancer prevention. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER. 2006 Aug;1766(1):63-78.
Jordan VC. Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen - A personal perspective. ONCOLOGY-NEW YORK. 2006 May;20(6):553-62.
Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. INTERNATIONAL JOURNAL OF ONCOLOGY. 2006 Nov;29(5):1237-46.
O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. CLINICAL CANCER RESEARCH. 2006 Jan;12(7):2255-63.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark NG. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Jun;295(23):2727-41.
Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. American journal of obstetrics and gynecology. 2005 Apr;192(4):1230-7.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute. 2005 Nov 16;97(22):1652-62.
Gorla SR, Hou N, Acharya S, Rademaker A, Khan S, Staradub V, Morrow M. A predictive model for the development of hormone-responsive breast cancer. Annals of Surgical Oncology. 2005 Jan;12(1):48-56.
Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Journal of the National Cancer Institute. 2005 Jan 05;97(1):30-9.
Jordan VC. Chemoprevention in the 21st century: Is a balance best or should women have no estrogen at all?. Journal of Clinical Oncology. 2005 Mar 10;23(8):1598-600.
Jordan VC, Lewis JS, Osipo C, Cheng D. The apoptotic action of estrogen following exhaustive antihormonal therapy: A new clinical treatment strategy. Breast. 2005 Dec;14(6):624-30.
Osipo C, Gajdos C, Cheng D, Jordan VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Journal of Steroid Biochemistry and Molecular Biology. 2005 Feb;93(2-5):249-56.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term postmenopausal women

postmenopausal women randomized-trial estrogen-receptor risk-factors Oncology mammary-carcinoma model athymic mice tamoxifen therapy mutations breast cancer estrogen receptor adjuvant therapy receptor endocrine therapy tamoxifen anastrozole in-vitro recurrence hot flashes progesterone-receptor status cytochrome-p450 2d6 combination randomized controlled-trial bowel project p-1 chemoprevention outcomes sex-hormones mammographic density surgical adjuvant breast survival breast-cancer Aromatase inhibitors risk zd1839 iressa low-fat tumor-antigens estrogen-receptor modulators apoptosis multidrug-resistance Biochemistry & Molecular Biology plasma carotenoids allele frequency fulvestrant health survey sf-36 Tamoxifen pharmacogenomics Breast cancer-CYP2D6-Poor metaboliser-Drug interaction breast neoplasms lines resistant molecular ovarian-cancer subtypes antihormonal therapy japanese population epidemiology depurinating estrogen-DNA adduct tumor growth ultrarapid metabolism positive cancers early breast-cancer estrogen antiestrogens plasma-lipids monoclonal-antibody performance liquid-chromatography prostate-cancer adjuvant tamoxifen therapy serum-cholesterol 474 tamoxifen ici 46 older women drug-resistance younger women toremifene adipose-tissue epithelial-cells black womens health metaanalysis autoantibodies breast cancer-biomarker-proteomics-protein microarrays General & Internal Medicine raloxifene mammary-carcinoma transporter abcg2 therapy epidemiologic characteristics cancer risk saturated fat iowa womens health hormone-levels carcinoma in-situ aromatase inhibitors cdna libraries serum-lipoproteins growth-factor receptor tumors depurinating dna-adducts replacement therapy bone-mineral density EGFR risk model endometrial carcinoma tamoxifen ER-estradiol-breast cancer paroxetine parenchymal patterns prognostic-factors rat uterus tamoxifen resistance relative imbalances humoral immune-response cancer initiation population expression oncology-technology-assessment vitamin-e levels Biophysics resistant mcf-7 cells carcinoma multiple outcomes phenotype randomized-trials follow-up serum carotenoids premenopausal women lipoprotein cholesterol basal receiving adjuvant tamoxifen long-term tamoxifen basal-like triple-negative-breast cancer-outcomes-brain metastases-obesity-race growth-factor-i predicting response atac arimidex estradiol chemosensitivity antithrombin-iii cell carcinoma endometrial dehydroepiandrosterone-sulfate prospective cohort carcinogenicity beta-carotene mammary-gland alcohol-consumption management tumor-growth pure antiestrogen aromatase activities tyrosine kinase inhibitor breast cancer resistant protein trial trastuzumab advanced breast-cancer human-breast-cancer nsabp
Last updated on Monday, August 10, 2020